Regulation of TGF-β1-driven differentiation of human Lung fibroblasts: Emerging roles of cathepsin B and cystatin C

Journal of Biological Chemistry

Volumn 289, Issue 23, 2014, Pages 16239-16251

  Kasabova, Mariana ^a   Joulin Giet, Alix ^a   Lecaille, Fabien ^a   Gilmore, Brendan F ^b   Marchand Adam, Sylvain ^a   Saidi, Ahlame ^a   Lalmanach, Gilles ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOLOGICAL ORGANS; CELL CULTURE; ENZYME ACTIVITY; PHOSPHORYLATION; PROTEINS; RESPIRATORY SYSTEM;

HUMAN LUNG FIBROBLASTS; IDIOPATHIC PULMONARY FIBROSIS; MRNA EXPRESSION; MYOFIBROBLASTS; PHARMACOLOGICAL INHIBITION; PROTEOLYTIC ACTIVITIES; RELATIVE CONTRIBUTION; SMOOTH MUSCLE ACTINS;

FIBROBLASTS;

ALPHA SMOOTH MUSCLE ACTIN; BREFELDIN A; CATHEPSIN B; CYSTATIN C; MESSENGER RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BIOACCUMULATION; CELL DIFFERENTIATION; CONTROLLED STUDY; EXTRACELLULAR SPACE; FIBROSING ALVEOLITIS; GENE SILENCING; HUMAN; HUMAN CELL; LUNG FIBROBLAST; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

COLLAGEN; CYSTEINE PROTEASE; PROTEASE; PROTEASE INHIBITOR; PULMONARY FIBROSIS; SMAD PATHWAY;

BLOTTING, WESTERN; CATHEPSIN B; CELL DIFFERENTIATION; CELLS, CULTURED; CYSTATIN C; FIBROBLASTS; GENE SILENCING; HUMANS; LUNG; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84902213879     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.542407     Document Type: Article

References (65)

1. Bjoraker, J. A., Ryu, J. H., Edwin, M. K., Myers, J. L., Tazelaar, H. D., Schroeder, D. R., and Offord, K. P. (1998) Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 157, 199-203
2. Raghu, G., Freudenberger, T. D., Yang, S., Curtis, J. R., Spada, C., Hayes, J., Sillery, J. K., Pope, C. E., and Pellegrini, C. A. (2006) High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 27, 136-142
3. Adamali, H. I., and Maher, T. M. (2012) Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des. Devel. Ther. 6, 261-271
4. Border, W. A., and Noble, N. A. (1994) Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331, 1286-1292
5. Khalil, N., Parekh, T., O'Connor, R., Antman, N., Kepron, W., Yehaulaeshet, T., Xu, Y., and Gold, L. (2001) Regulation of the effects of TGF-β1 by activation of latent TGF-β1 and differential expression of TGF-β receptors (TβR-I and TβR-II) in idiopathic pulmonary fibrosis. Thorax 56, 907-915
6. Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., and Gabbiani, G. (2007) The myofibroblast: one function, multiple origins. Am. J. Pathol. 170, 1807-1816
7. Desmouliere, A., Geinoz, A., Gabbiani, F., and Gabbiani, G. (1993) Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 122, 103-111
8. Kasabova, M., Saidi, A., Naudin, C., Sage, J., Lecaille, F., and Lalmanach, G. (2011) Cysteine Cathepsins: Markers and Therapy Targets in Lung Disorders. Clin. Rev. Bone Miner. Metab. 9, 148-161
9. Lecaille, F., Kaleta, J., and Bromme, D. (2002) Human and parasitic papainlike cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 102, 4459-4488
10. Novinec, M., and Lenarcic, B. (2013) Cathepsin K: a unique collagenolytic cysteine peptidase. Biol. Chem. 394, 1163-1179
11. Rawlings, N. D., Barrett, A. J., and Bateman, A. (2012) MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 40, D343-D350
12. Turk, V., Stoka, V., Vasiljeva, O., Renko, M., Sun, T., Turk, B., and Turk, D. (2012) Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta 1824, 68-88
13. Brix, K., Dunkhorst, A., Mayer, K., and Jordans, S. (2008) Cysteine cathepsins: cellular roadmap to different functions. Biochimie (Paris) 90, 194-207
14. Reiser, J., Adair, B., and Reinheckel, T. (2010) Specialized roles for cysteine cathepsins in health and disease. J. Clin. Invest. 120, 3421-3431
15. Turk, B. (2006) Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5, 785-799
16. Vasiljeva, O., Reinheckel, T., Peters, C., Turk, D., Turk, V., and Turk, B. (2007) Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 13, 387-403
17. Abrahamson, M., Alvarez-Fernandez, M., and Nathanson, C.-M. (2003) Cystatins. Biochem. Soc. Symp. 179. 199
18. Turk, V., Stoka, V., and Turk, D. (2008) Cystatins: biochemical and structural properties, and medical relevance. Front. Biosci. 13, 5406-5420
19. Canbay, A., Guicciardi, M. E., Higuchi, H., Feldstein, A., Bronk, S. F., Rydzewski, R., Taniai, M., and Gores, G. J. (2003) Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J. Clin. Invest. 112, 152-159
20. Moles, A., Tarrats, N., Fernandez-Checa, J. C., and Mari, M. (2009) Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology 49, 1297-1307
21. Chen, H., Wang, J., Xiang, M.-X., Lin, Y., He, A., Jin, C.-N., Guan, J., Sukhova, G. K., Libby, P., Wang, J.-A., and Shi, G.-P. (2013) Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction. Cardiovasc. Res. 100, 84-94
22. Lalmanach, G., Diot, E., Godat, E., Lecaille, F., and Herve-Grepinet, V. (2006) Cysteine cathepsins and caspases in silicosis. Biol. Chem. 387, 863-870
23. Quinn, D. J., Weldon, S., and Taggart, C. C. (2010) Antiproteases as therapeutics to target inflammation in cystic fibrosis. Open Respir. Med. J. 4, 20-31
24. Buhling, F., Rocken, C., Brasch, F., Hartig, R., Yasuda, Y., Saftig, P., Bromme, D., and Welte, T. (2004) Pivotal role of cathepsin K in lung fibrosis. Am. J. Pathol. 164, 2203-2216
25. Zhang, D., Leung, N., Weber, E., Saftig, P., and Bromme, D. (2011) The effect of cathepsin K deficiency on airway development and TGF-β1 degradation. Respir. Res. 12, 72
26. Zhang, D., Huang, C., Yang, C., Liu, R. J., Wang, J., Niu, J., and Bromme, D. (2011) Antifibrotic effects of curcumin are associated with overexpression of cathepsins K and L in bleomycin treated mice and human fibroblasts. Respir. Res. 12, 154
27. Van den Brule, S., Misson, P., Buhling, F., Lison, D., and Huaux, F. (2005) Overexpression of cathepsin K during silica-induced lung fibrosis and control by TGF-beta. Respir. Res. 6, 84
28. Gerber, A., Wille, A., Welte, T., Ansorge, S., and Buhling, F. (2001) Interleukin-6 and transforming growth factor-beta 1 control expression of cathepsins B and L in human lung epithelial cells. J. Interf. Cytokine Res. 21, 11-19.
29. Lalmanach, G., Mayer, R., Serveau, C., Scharfstein, J., and Gauthier, F. (1996) Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Biochem. J. 318, 395-399
30. Akamine, A., Raghu, G., and Narayanan, A. S. (1992) Human lung fibroblast subpopulations with different C1q binding and functional properties. Am. J. Respir. Cell Mol. Biol. 6, 382-389
31. Zi, Z., Feng, Z., Chapnick, D. A., Dahl, M., Deng, D., Klipp, E., Moustakas, A., and Liu, X. (2011) Quantitative analysis of transient and sustained transforming growth factor-β signaling dynamics. Mol. Syst. Biol. 7, 492
32. Serveau-Avesque, C., Ferrer-di Martino, M., Hervé-Grépinet, V., Hazouard, E., Gauthier, F., Diot, E., and Lalmanach, G. (2006) Active cathepsins B, H, K, L and S in human inflammatory bronchoalveolar lavage fluids. Biol. Cell 98, 15-22
33. Assfalg-Machleidt, I., Billing, A., Fröhlich, D., Nast-Kolb, D., Joka, T., Jochum, M., and Machleidt, W. (1992) The role of the kininogens as cysteine proteinase inhibitors in local and systemic inflammation. Agents Actions. Suppl. 38, 312-321
34. Florent, I., Lecaille, F., Montagne, J.-J., Gauthier, F., Schrével, J., and Lalmanach, G. (2005) Labelling of four distinct trophozoite falcipains of Plasmodium falciparum by a cystatin-derived probe. Biol. Chem. 386, 401-406
35. Srivastava, M., Steinwede, K., Kiviranta, R., Morko, J., Hoymann, H.-G., Länger, F., Buhling, F., Welte, T., and Maus, U. A. (2008) Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis. Respir. Res. 9, 54
36. Moles, A., Tarrats, N., Fernández-Checa, J. C., and Marí, M. (2012) Cathepsin B overexpression due to acid sphingomyelinase ablation promotes liver fibrosis in Niemann-Pick disease. J. Biol. Chem. 287, 1178-1188
37. Perdereau, C., Godat, E., Maurel, M.-C., Hazouard, E., Diot, E., and Lalmanach, G. (2006) Cysteine cathepsins in human silicotic bronchoalveolar lavage fluids. Biochim. Biophys. Acta 1762, 351-356
38. Naudin, C., Joulin-Giet, A., Couetdic, G., Plésiat, P., Szymanska, A., Gorna, E., Gauthier, F., Kasprzykowski, F., Lecaille, F., and Lalmanach, G. (2011) Human cysteine cathepsins are not reliable markers of infection by Pseudomonas aeruginosa in cystic fibrosis. PLoS ONE 6, e25577
39. Takeyabu, K., Betsuyaku, T., Nishimura, M., Yoshioka, A., Tanino, M., Miyamoto, K., and Kawakami, Y. (1998) Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Eur. Respir. J. 12, 1033-1039
40. Jane, D. T., Morvay, L., Dasilva, L., Cavallo-Medved, D., Sloane, B. F., and Dufresne, M. J. (2006) Cathepsin B localizes to plasma membrane caveolae of differentiating myoblasts and is secreted in an active form at physiological pH. Biol. Chem. 387, 223-234
41. Buttle, D. J., Murata, M., Knight, C. G., and Barrett, A. J. (1992) CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch. Biochem. Biophys. 299, 377-380
42. Jenkins, G. (2008) The role of proteases in transforming growth factorbeta activation. Int. J. Biochem. Cell Biol. 40, 1068-1078
43. Biernacka, A., Dobaczewski, M., and Frangogiannis, N. G. (2011) TGF-β signaling in fibrosis. Growth Factors 29, 196-202
44. Daley, W. P., Peters, S. B., and Larsen, M. (2008) Extracellular matrix dynamics in development and regenerative medicine. J. Cell Sci. 121, 255-264
45. Purchio, A. F., Cooper, J. A., Brunner, A. M., Lioubin, M. N., Gentry, L. E., Kovacina, K. S., Roth, R. A., and Marquardt, H. (1988) Identification of mannose 6-phosphate in two asparagine-linked sugar chains of recombinant transforming growth factor-beta 1 precursor. J. Biol. Chem. 263, 14211-14215
46. Somanna, A., Mundodi, V., and Gedamu, L. (2002) Functional analysis of cathepsin B-like cysteine proteases from Leishmania donovani complex. Evidence for the activation of latent transforming growth factor beta. J. Biol. Chem. 277, 25305-25312
47. Gogineni, V. R., Gupta, R., Nalla, A. K., Velpula, K. K., and Rao, J. S. (2012) uPAR and cathepsin B shRNA impedes TGF-β1-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway. Cell Death Dis. 3, e439
48. Brunner, A. M., Gentry, L. E., Cooper, J. A., and Purchio, A. F. (1988) Recombinant type 1 transforming growth factor beta precursor produced in Chinese hamster ovary cells is glycosylated and phosphorylated. Moll. Cell Biol. 8, 2229-2232
49. Gauldie, J., Kolb, M., Ask, K., Martin, G., Bonniaud, P., and Warburton, D. (2006) Smad3 signaling involved in pulmonary fibrosis and emphysema. Proc. Am. Thorac. Soc. 3, 696-702
50. Shi, Y., and Massagué, J. (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700
51. Reddy, V. Y., Zhang, Q. Y., and Weiss, S. J. (1995) Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc. Natl. Acad. Sci. U. S. A. 92, 3849-3853
52. Sukhova, G. K., Shi, G. P., Simon, D. I., Chapman, H. A., and Libby, P. (1998) Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 102, 576-583
53. Shi, G.-P., Sukhova, G. K., Grubb, A., Ducharme, A., Rhode, L. H., Lee, R. T., Ridker, P. M., Libby, P., and Chapman, H. A. (1999) Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J. Clin. Invest. 104, 1191-1197
54. Gressner, A. M., Lahme, B., Meurer, S. K., Gressner, O., and Weiskirchen, R. (2006) Variable expression of cystatin C in cultured trans-differentiating rat hepatic stellate cells. World J. Gastroenterol. 12, 731-738
55. Chung-Hung, T., Shun-Fa, Y., and Yu-Chao, C. (2007) The upregulation of cystatin C in oral submucous fibrosis. Oral Oncol. 43, 680-685
56. Koslowski, R., Knoch, K., Kuhlisch, E., Seidel, D., and Kasper, M. (2003) Cathepsins in bleomycin-induced lung injury in rat. Eur. Respir. J. 22, 427-435
57. Gabbiani, G. (2003) The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200, 500-503
58. Heidtmann, H. H., Salge, U., Havemann, K., Kirschke, H., and Wiederanders, B. (1993) Secretion of a latent, acid activatable cathepsin L precursor by human non-small cell lung cancer cell lines. Oncol. Res. 5, 441-451
59. Bühling, F., Gerber, A., Häckel, C., Krüger, S., Köhnlein, T., Brömme, D., Reinhold, D., Ansorge, S., and Welte, T. (1999) Expression of cathepsin K in lung epithelial cells. Am. J. Respir. Cell Mol. Biol. 20, 612-619
60. Andl, C. D., McCowan, K. M., Allison, G. L., and Rustgi, A. K. (2010) Cathepsin B is the driving force of esophageal cell invasion in a fibroblastdependent manner. Neoplasia 12, 485-498
61. Yin, M., Soikkeli, J., Jahkola, T., Virolainen, S., Saksela, O., and Hölttä, E. (2012) TGF-β Signaling, Activated Stromal Fibroblasts, and Cysteine Cathepsins B and L Drive the Invasive Growth of Human Melanoma Cells. Am. J. Pathol. 181, 2202-2216
62. Guo, M., Mathieu, P. A., Linebaugh, B., Sloane, B. F., and Reiners, J. J., Jr (2002) Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betaL a process initiated by the exocytosis of cathepsin B. J. Biol. Chem. 277, 14829-14837
63. Montaser, M., Lalmanach, G., and Mach, L. (2002) CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells. Biol. Chem. 383, 1305-1308
64. Xie, L., Terrand, J., Xu, B., Tsaprailis, G., Boyer, J., and Chen, Q. M. (2010) CystatinCincreases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc. Res. 87, 628-635
65. Kasabova, M., Joulin-Giet, A., Lecaille, F., Saidi, A., Marchand-Adam, S., and Lalmanach, G. (2013) Human cystatin C: a new biomarker of idiopathic pulmonary fibrosis. Proteomics Clin. Appl., 10.1002/prca.201300047